EBNA 2 is one of only five viral genes essential for the infection and immortalization of human B cells by the cancer-associated virus Epstein-Barr virus (EBV). EBNA 2 activates cellular and viral transcription and associates with components of the basal transcription apparatus and a number of coactivators. We provide the first evidence to show that the mechanism of transcriptional activation by EBNA 2 also involves phosphorylation of the C-terminal domain (CTD) of RNA polymerase II (pol II). We found that transcriptional activation by EBNA 2 was inhibited by a dominant-negative mutant of the pol II CTD kinase, CDK9, and by low concentrations of the CDK9 inhibitor 5, 6-dichloro-1-b-D-ribofuranosylbenzimidazole. Moreover, using chromatin immunoprecipitation assays we demonstrated that EBNA 2 stimulates both pol II recruitment and pol II phosphorylation on serine 5 of the CTD in vivo. These results identify a new step in the transcription cycle that is subject to regulation by a key EBV-encoded transcription factor and highlight CDK9 inhibitors as potential anti-EBV agents.
Introduction
The DNA tumour virus Epstein-Barr virus (EBV) was the first virus to be isolated from a tumour biopsy sample and to be implicated in the development of human cancer. EBV has potent transforming properties in vitro and is able to infect and immortalize resting human B cells, establishing a persistent latent infection within the resulting lymphoblastoid cell line. Only nine of the 80 or so genes encoded by EBV are translated during latency and only five of these have been shown to be essential for infection and immortalization; EBV nuclear antigens (EBNAs) 1, 2, 3A and 3C and latent membrane protein 1 (LMP 1) (Skare et al., 1985; Cohen et al., 1989; Kaye et al., 1993; Tomkinson et al., 1993; Lee et al., 1999) .
EBNA 2 functions as an activator of both viral and cellular transcription and is targeted to its responsive elements through interactions with the cellular DNAbinding proteins RBP-Jk and PU.1. (Ling et al., 1993; Grossman et al., 1994; Henkel et al., 1994; Waltzer et al., 1994; Zimber-Strobl et al., 1994; Johannsen et al., 1995; Sjoblom et al., 1995) . EBNA 2 activates the viral C promoter (Cp), from where the long (up to 120 kB) primary transcript encoding all six of the EBNAs initiates, in addition to the promoters of all three LMP genes (Abbot et al., 1990; Wang et al., 1990) . EBNA 2 is one of the first viral proteins to be expressed following viral infection (8-12 h) (Allday et al., 1989; Alfieri et al., 1991) but the mRNA encoding EBNA 2 initially originates from the W promoter (Wp), an alternative EBNA promoter located downstream from Cp. The switching of promoter usage from Wp to Cp appears to be a direct consequence of the activation of Cp by EBNA 2 and leads to the expression of the remaining EBNAs (1, 3A, 3B and 3C) (Woisetschlaeger et al., 1991) .
The mechanism by which EBNA 2 activates transcription has been the subject of intensive study over the years. EBNA 2 contains a region that functions as an acidic activation domain and can be replaced by the acidic activation domain of VP16 (Cohen and Kieff, 1991; Cohen, 1992) . Like many transcriptional activator proteins, EBNA 2 is able to interact with components of the basal transcription machinery in addition to a number of transcriptional coactivator proteins. Thus far, EBNA 2 has been shown to interact with TFIIB, TAF40, the p62 and XPD (p80) subunits of TFIIH, a 100 kDa protein that associates with TFIIE, hSNF5, p300, CBP and PCAF (Tong et al., 1995a, b, c; Wu et al., 1996; Wang et al., 2000) . EBNA 2 has also been shown to promote Histone H3 and H4 acetylation at the Cp and LMP 1 promoters in vivo (Alazard et al., 2003) .
Although attracting polymerase complexes to the promoter in addition to promoting the formation of an 'open' chromatin state to allow these complexes to access promoter DNA are crucial regulatory points for the control of transcriptional initiation, phosphorylation of the C-terminal domain (CTD) of pol II is also required for efficient initiation, promoter clearance and elongation. The CTD consists of 52 repeats of a heptapeptide sequence and becomes phosphorylated during transcription on serines 2 and 5 (for review see Palancade and Bensaude, 2003) . A number of viral and cellular transcription factors have been shown to regulate CTD phosphorylation by recruiting or modulating the activity of the transcription-associated CTD kinases, CDK7, CDK8 or CDK9. Isel and Karn, 1999; Lee et al., 2001; Eberhardy and Farnham, 2002; Spilianakis et al., 2003; Tian et al., 2003) . These CTD kinases and their respective cyclin partners form part of large multiprotein complexes. CDK7 and cyclin H are subunits of the general transcription factor TFIIH, CDK8 and cyclin C are components of mediator and CDK9 forms part of the Tat-associated kinase, TAK (pTEF-b).
We set out to investigate whether the regulation of RNA polymerase II (pol II) CTD phosphorylation plays a role in the mechanism of transcriptional activation by the key EBV latent transcriptional activator, EBNA 2.
Results

EBNA 2-activated transcription is inhibited by a dominant-negative (dn) mutant of CDK9
To determine whether the activation of transcription by EBNA 2 was dependent on the activities of the transcription-associated CTD kinases CDK7, 8 or 9, we performed EBNA 2 activation assays in the presence of dn CTD kinase mutants (Figure 1 ). We found that expression of dnCDK9 (D167N) dramatically inhibited EBNA 2-activated transcription from a Cp reporter construct, but had very little effect on the level of Cp basal transcription (Figure 1a and d) . In the presence of 3 mg of D167N-expressing plasmid, EBNA 2-activated transcription was reduced to 38% of its original level, whereas transcription from Cp in the absence of EBNA 2 remained at 77% (Figure 1d ). By contrast, the expression of dnCDK8 (D173A) had no effect on basal or EBNA 2-activated transcription (Figure 1b and e) . Experiments carried out using dnCDK7 (K41M) indicated that both EBNA 2-activated and basal transcription from Cp were not particularly dependent on CDK7 kinase activity with only small effects observed in the presence of high levels of K41M (Figure 1c and f) . These results are consistent with the general requirement for CDK7 activity for efficient initiation and promoter clearance. In all cases dnCDKs were expressed up to levels equivalent to those of the endogenous kinases ( Figure 1a , b and c, lower panels). These results indicate that CDK9 plays a crucial role in the EBNA 2 activation mechanism but that CDK7 and CDK8 do not appear to be specifically targeted by EBNA 2.
Since EBNA 2 is also a potent activator of the viral LMP 1 promoter (LMP 1p) we examined whether EBNA 2 activation of this promoter was sensitive to inhibition by dnCDKs. In contrast to Cp, where EBNA 2 is targeted to the promoter solely through an interaction with the cellular DNA-binding protein RBP-Jk, EBNA 2 is directed to LMP 1p through both RBP-Jk and PU.1 (Johannsen et al., 1995) . Again, our results showed that EBNA-2-activated transcription was dependent on the kinase activity of CDK9 (Figure 2 ), but not that of CDK8 or CDK 7 (data not shown). It is therefore clear that the requirement for CDK9 activity is not affected by the mechanism of EBNA 2 recruitment to the promoter.
EBNA 2-activated transcription is inhibited by the CDK9 inhibitor 6-dichloro-1-b-D-ribofuranosylbenzimidazole (DRB) To further confirm the dependency of EBNA 2-activated transcription on the activity of CDK9, experiments were performed in the presence of the kinase inhibitors DRB and H-8. Both of these drugs reduce transcription rates by inhibiting the phosphorylation of the CTD (Dubois et al., 1994) . CDK9 has been shown to be approximately 10 times more sensitive to inhibition by DRB than H-8 (Marshall et al., 1996) . TFIIH (CDK7) on the other hand does not appear to be sensitive to inhibition by low levels of DRB and appears to be more sensitive to inhibition by H-8 (Marshall et al., 1996; Isel and Karn, 1999) . We found that EBNA 2-activated transcription from the C and LMP 1 promoters was sensitive to inhibition by low levels of DRB but not to inhibition by the same concentrations of H-8 (Figure 3 ). These results confirm that EBNA 2 is unable to activate transcription efficiently when the CTD kinase activity of CDK9 is inhibited. dnCDK9 and DRB do not affect cdc2 kinase activity or EBNA 2 phosphorylation Recent studies have shown that hyperphosphorylation of EBNA 2 suppresses its ability to activate the LMP 1 promoter and reduces its association with PU.1 (Yue et al., 2004 (Yue et al., , 2005 . Since it is possible that the reduced EBNA 2 activation we observed in the presence of dnCDK9 or DRB resulted from alterations in the level of EBNA 2 phosphorylation in response to these agents, we examined the phosphorylation of EBNA 2 in more detail. Initial experiments were carried out to determine the effects of dnCDK9 and DRB on the activity of p34cdc2, the kinase implicated in EBNA 2 hyperphosphorylation during mitosis (Yue et al., 2004) . We found that the kinase activity of p34cdc2 was unaffected by either dnCDK9 or DRB (Figure 4 ). We next examined whether the phosphorylation state of EBNA 2 was altered in the presence of DRB or dnCDK9. EBNA 2 was immunoprecipitated from cells expressing dnCDK9 or treated with DRB and incubated in the presence or absence of alkaline phosphatase to aid the identification of the phosphorylated and unphosphorylated forms of the protein using SDS-PAGE. We detected phosphorylated forms of EBNA 2 in control cells, in dnCDK9-expressing cells and in DRB-treated cells ( Figure 5 ). In all cases we observed an increase in the mobility of EBNA 2 following alkaline phosphatase treatment consistent with the removal of phosphate groups from the protein ( Figure 5 ). No increase in the level of EBNA 2 phosphorylation was observed in the presence of dnCDK9 or DRB ( Figure 5 ) that could account for the inhibition of EBNA 2 activation of the C and LMP 1 promoters we observed (Figures 1-3 ). It is most likely therefore that the inhibition of EBNA 2 activation observed in the presence of dnCDK9 and DRB results from the inhibition of CDK9 activity and is not the result of an alteration in the phosphorylation state of EBNA 2.
EBNA 2 can activate transcription through histone acetylation-independent mechanisms Our results identifying the involvement of a CTD kinase in the EBNA 2 activation mechanism suggest that EBNA 2 is able to activate transcription through histone acetylation-independent mechanisms. To test this hypothesis we measured the levels of EBNA 2-activated transcription in the presence of the histone deacetylase inhibitor, Trichostatin A (TSA). The inhibition of histone deacetylase activity by TSA leads to global increases in histone acetylation and results in promoter activation. Cells were transfected with Cp reporter and EBNA 2-expressing plasmids and treated with TSA after 24 h. The levels of RNA transcripts derived from Cp in the absence and presence of EBNA 2 were then measured directly by RNase protection analysis using two different antisense RNA probes ( Figure 6 ). We detected an approximately fourfold increase in the level of transcripts derived from Cp following treatment with 400 nM TSA in the absence of EBNA 2 (Figure 6b-d) . These results confirmed that the Cp could be activated by histone acetylation. Interestingly, we found that EBNA 2 retained the ability to activate transcription in the presence of 200 or 400 nM TSA (Figure 6b The phosphorylation state of EBNA 2 is not affected by dnCDK9 or DRB. DG75 cells were transfected with 10 mg of pSG52A and either 3 mg FLAG vector or 3 mg dnCDK9-expressing plasmid were indicated, or treated with 30 mM DRB. EBNA 2 was immunoprecipitated using the PE2 monoclonal antibody and samples were incubated in alkaline phosphase buffer in the absence (À) or presence ( þ ) of calf intestinal alkaline phosphatase. Samples were separated by SDS-PAGE and EBNA 2 detected by immunoblotting with PE2. mechanisms. Our data indicate that at least one of these mechanisms is likely to involve phosphorylation of the CTD by CDK9.
EBNA 2 stimulates CTD phosphorylation in vivo Since our data indicated that the kinase activity of CDK9 was required for EBNA 2 to efficiently activate transcription, we next tested whether we could detect an increase in (pol II) CTD phosphorylation in the presence of EBNA 2 in vivo using chromatin immunoprecipitation (ChIP) assays. These experiments were carried out using a cell line expressing an estrogen receptor-EBNA 2 fusion protein that is only active in the presence of b-estradiol (Kempkes et al., 1995) . Immunoprecipitations using an anti-EBNA 2 antibody confirmed that EBNA 2 bound to upstream regions of Cp at fivefold higher levels in the presence of b-estradiol, with the peak signal detected, as expected, around the RBP-Jk site (Figure 7b ). Anti-pol II immunoprecipitations detected a 2.3-fold increase in the association of pol II with DNA around the transcription start site in the presence of b-estradiol, indicating that EBNA 2 promotes the recruitment of pol II to the promoter (Figure 7c ). Strikingly, we found that in addition to stimulating pol II recruitment, EBNA 2 also promoted CTD phosphorylation. Using an antiphospho-serine 5 antibody (H14), we detected a 2.8-3.4-fold increase in the amount of serine 5-phosphorylated pol II at regions both upstream and downstream from the transcription start site in the presence of b-estradiol ( Figure 7d ). As expected, the distribution pattern of the serine 5-phosphorylated pol II ChIP signal matched the regions of the template to which pol II was bound (Figure 7c and d) but did not match the regions of the template to which EBNA 2 was bound (Figure 7b and d) . When we investigated the effects of EBNA 2 on serine 2 phosphorylation, we found that phospho-serine 2 epitopes were only detectable at background levels in the absence or presence of EBNA 2 with primer sets 1-4 (Figure 8b ). In fact, the signal obtained in antiphospho-serine 2 ChIPs using these primers sets (1-4) was no higher than the background signal obtained using control EBV primers (Figure 8b and c) . Since serine 2 phosphorylation is present at highest levels at the 3 0 end of genes (Komarnitsky et al., 2000) we carried out ChIP analysis using primers designed to amplify regions much further downstream from the promoter. The ER/EB2-5 cells used in this study contain a mutant EBV lacking EBNA 2 (P3HR1) and a mini-EBV plasmid that encodes an ER/EBNA 2 fusion protein in trans. Both contain ER/EBNA 2-responsive Cps and primer sets 1-4 detect both templates. Owing to the deletion in P3HR1, our downstream primers (sets 5 and 6) detect only mini-EBV sequences (Figure 8a ). Consistent with previous reports (Komarnitsky et al., 2000) we found a dramatic increase in serine 2 phosphorylation at 3 0 regions of the template (Figure 8c ). The signal obtained using primer sets 5 and 6 was significantly higher than the signal obtained using control primers indicating that serine 2-phosphorylated polymerases were present at downstream regions of the template (Figure 8c ). However, we did not detect any consistent effect of b-estradiol on the levels of serine 2 phosphorylation (Figure 8c and data not shown) indicating that EBNA 2 does not promote serine 2 phosphorylation. Further confirmation that the downstream phospho-serine 2 signal we detected did not represent high levels of nonspecific background detected with these primer sets came from experiments carried out using anti-EBNA 2 antibodies (Figure 8d and e). In anti-EBNA 2 ChIP assays, EBNA 2 was clearly detectable around the RBP-Jk at increased levels in the presence of b-estradiol, but was not detectable at downstream regions of the template using primer sets 5 and 6 above the level detected with control primers (Figure 8e ). In contrast, we observed dramatic increases in the level of serine 5-phosphorylated pol II in the presence of b-estradiol using these downstream primer sets indicating that EBNA 2 promotes serine 5 but not serine 2 phophorylation of pol II (Figure 8i ).
Discussion
We set out to investigate whether pol II phosphorylation was regulated by the essential EBV transcriptional regulator EBNA 2 and have identified the CTD kinase CDK9 as a key player in the EBNA 2 activation mechanism. These results identify a new step in the transcription cycle that is subject to regulation by an EBV-encoded transcription factor and provide further vital information on the mechanism of action of EBNA 2. We propose a new three-step model for the activation of transcription by EBNA 2 (Figure 9 ). RNA pol II is recruited to the promoter in a hypophosphorylated form (II a ) and is converted into a hyperphosphorylated form (II o ) during transcription largely through the phosphorylation of serine residues at positions 2 and 5 in the CTD repeat region of its largest subunit (Rpb1) (reviewed in Palancade and Bensaude, 2003) . Although serine 2 phosphorylation has been closely linked to CDK9 activity, CDK9 has been shown to phosphorylate both serine 2 and 5 in elongation complexes established on HIV-1 templates (Kim et al., 2002) , to preferentially phosphorylate serine 5 on peptides (Ramanathan et al., 2001) and to have increased activity towards serine 5 in the presence of HIV-1 Tat (Zhou et al., 2000) . Our results indicate that EBNA 2 promotes phosphorylation on serine 5 of the pol II CTD. Given that the activation of transcription by EBNA 2 is extremely sensitive to inhibition by dnCDK9 and the CDK9 inhibitor, DRB, it is likely that the increase in serine 5 phosphorylation we have detected is the result of CDK9 activity. Our results are consistent with a model whereby EBNA 2 recruits or activates CDK9 resulting in the stimulation of CTD phosphorylation on serine 5 (Figure 7) . Consistent with the results of in vitro experiments carried out by other authors , and despite many attempts, we have been unable to detect a direct interaction between EBNA 2 and CTD kinases in vivo (data not shown). It is therefore possible that CDK9 associates with EBNA 2 indirectly through other components of TAK, as reported for the c-Myc transcription factor (Eberhardy and Farnham, 2002) , or associates with the promoter through interactions with components of the transcription machinery (Isel and Karn, 1999; Ping and Rana, 1999) . Whatever the mechanism of CDK9 recruitment to EBNA 2-responsive promoters, it is clear from our results that CDK9 plays an important functional role in the EBNA 2 transcription activation mechanism.
Phosphorylation of the CTD is required for promoter clearance and for the efficient elongation of the RNA transcript. Although CDK7 and CDK8 are involved in the regulation of CTD phosphorylation during initiation and promoter clearance, CDK9 appears to play an additional role in the regulation of transcription elongation. The HIV-1 activator protein, Tat, has been shown to stimulate transcriptional elongation through CDK9-dependent CTD phosphorylation and CDK9 is the only CTD kinase that can travel with the elongating polymerase (Isel and Karn, 1999; Kim et al., 2002) . Since we have identified a requirement for CDK9 for the efficient activation of transcription by EBNA 2, our results raise the intriguing possibility that EBNA 2 may activate transcriptional elongation in addition to initiation. This may explain the important role played by EBNA 2 in the EBV life cycle in activating Cp and switching promoter usage from an alternative downstream EBNA promoter (Wp) used during initial infection. Transcription from Wp leads only to the expression of genes at the 5 0 end of the EBV template (EBNA 2 and LP). EBNA 2-activation of Cp is required for the production of the long primary transcript (up to 120 kB) encoding the remaining EBNAs (1, 3A, 3B and 3C) required for immortalization (Woisetschlaeger et al., 1991) and may represent a switch from poorly processive to CDK9-dependent processive (elongation competent) transcription. It is interesting to note that Wp is located in the IR-1 repeat region of the EBV genome and as a result is present in multiple copies (e.g. seven copies in the prototype Type 1 EBV strain, B95-8).
The duplication of the Wp may represent a mechanism to ensure that sufficient transcripts encoding EBNA 2 are generated early in infection. If transcription complexes assembled at the Wp are poorly processive, and the vast majority of transcription complexes disengage from the template prematurely, increasing the number of polymerases that initiate would increase the likelihood of some polymerases reaching the end of the template. This Wp duplication may explain why Cpdeleted viruses are able to transform B-cells (Swaminathan, 1996) . This would however represent a very wasteful transcription system and a switch to a more efficient promoter would be preferable.
The dependency of EBNA 2-activated transcription on CDK9 also raises the possibility that the anticancer drug and CDK9 inhibitor, flavopiridol (Chao et al., 2000) could be used as an anti-EBV agent. Flavopiridol is a small molecule cyclin-dependent kinase inhibitor originally isolated from an Indian plant and used for many years in indigenous medicines. This drug effectively inhibits CDKs at least 20-fold more selectively than other cellular kinases (Chao and Price, 2001; Sedlacek, 2001 ) and has been shown to block cell-cycle progression and promote apoptosis by inhibiting CDKs involved in cell-cycle regulation (Patel et al., 1998; Decker et al., 2001; Yu et al., 2002; Litz et al., 2003; Ma et al., 2003) . Phase I and II clinical trials of flavopiridol have been carried out on a number of solid and haematological cancers and more are currently underway (Wendtner et al., 2004; Van Veldhuizen et al., 2005) . Interestingly, flavopiridol has been shown to be a very selective inhibitor of CDK9 (IC50 of 3 nM) (Chao et al., 2000) . Given the requirement for CDK9 in the HIV-1 Tat transactivation mechanism (Zhu et al., 1997; Gold et al., 1998) , the potential use of flavopiridol as an anti-HIV agent is being investigated and early results in mice are promising (Nelson et al., 2003; Sadaie et al., 2004) . Our results identifying a requirement for CDK9 in the EBNA 2 activation mechanism pinpoint a stage in the latent infection process that could be targeted by flavopiridol to inhibit EBV-induced B-cell proliferation and immortalization. Potential applications of flavopiridol may be in the treatment of EBNA 2-positive EBVassociated tumours such as PTLD or to block EBNA 2-dependent B-cell proliferation in severe cases of infectious mononucleosis where the use of traditional antivirals has proved to be ineffective (reviewed in Andersson, 2000) .
Materials and methods
Cell lines DG75 cells were maintained as described previously (West et al., 2004) . ER/EB2-5 cells (gift from B Kempkes) were cultured in RPMI minus phenol red plus 10% foetal bovine serum, antibiotics and 1 mM b-estradiol (Sigma). Plasmids LMP 1p-GL2 which contains LMP 1 promoter sequences from -327 to þ 40, was generated by inserting a Bgl II fragment containing the bidirectional LMP 1/LMP 2B (TP2) promoter from plasmid TLO (gift from A Bell) into the Bgl II site of pGL2-basic (Promega) in the reverse orientation.
Plasmids used to generate probes for RNase protection analysis were created by cloning the relevant regions of Cp-1425-GL2 (West et al., 2004) into pBS SK þ (Stratagene). To create pBS SK þ prox, Cp-1425-GL2 was first linearized with Bsu 361 (À52) and end-filled, and then cleaved with NarI ( þ 72) to generate a Cp-1425-GL2 proximal fragment that was cloned in the reverse orientation between the ClaI and SmaI sites of pBS SK þ . To create pBS SK þ dist, Cp-1425-GL2 was linearized with SapI ( þ 844), end-filled, and then cleaved with EcoRI ( þ 629) to generate a distal fragment that was cloned in the reverse orientation between the HincII and EcoRI sites of pBS SK þ .
Transient transfections DG75 cells were transfected as described previously (West et al., 2004) . For luciferase assays, transfections contained 2 mg of Cp-1425-GL2 (West et al., 2004) or LMP 1p-GL2, 0 or 10 mg pSG52A (Tsang et al., 1991) and 2 mg of pRL-CMV (Promega). For dnCDK assays transfections also contained up to 40 mg of plasmid expressing the relevant dnCDK; pcDNA3-K41M (dnCDK7) (Makela et al., 1994) (gift from S Akoulitchev), pFLAG-CMV2-D173A (dnCDK8) or pFLAG-CMV2-D167N (dnCDK9) (gifts from A Rice) (Gold et al., , 1998 . DNA levels were kept constant using pSG5 vector or pFLAG-CMV2 vector.
For experiments using the kinase inhibitors 5, DRB (Sigma) or N-[2-(methylamino)-ethyl]-5-isoquinoline sulphonamide (H-8, Fisher Scientific), cells were transfected and then placed in media containing 10-30 mM DRB or H-8 or DMSO alone for 48 h.
For RNase protection analysis cells were transfected with 20 mg Cp-1425-GL2 and 0 or 15 mg pSG52A. RNA was extracted from four pooled transfections.
Cdc2 immunoprecipitations and kinase assays DG75 cells were either transfected with 3 mg of pFLAG-CMV2-vector or 3 mg pFLAG-CMV2-D167N (dnCDK9) and harvested after 48 h, or treated with 30 mM DRB for 48 h. Cells from two pooled transfections were lysed in 0.5 ml of EBC buffer for 30 min on ice, sonicated, and insoluble debris removed by centrifugation at 13 000 rpm for 5 min. Samples were precleared for 30 min using protein G-sepharose beads (Sigma) and then incubated with 2 mg of anti-cdc2 antibodies (sc-54, Santa Cruz Biotechnology Inc.) for 2.5 h at 41C. Immune complexes were collected by incubating with protein G-sepharose beads overnight and then washed three times in EBC buffer containing 0.03% SDS.
Immunoprecipitates were washed twice in kinase buffer (25 mM Tris pH 7.4, 10 mM MgCl 2 and 5 mM DTT) and onequarter of the sample was then incubated in kinase buffer containing 1 mCi g 32 P-ATP and 2 mg of Histone H1 for 30 min at 371C. The remaining sample was analysed by SDS-PAGE and the amount of cdc2 immunoprecipitated was determined by immunoblotting. Kinase assay samples were analysed by SDS-PAGE and phosphorylated Histone H1 was visualized by autoradiography and the signal quantified using a phosphorimager.
Immunoprecipitation of EBNA 2 and phosphatase treatment DG75 cells were either transfected with pSG52A in the presence of 3 mg of pFLAG-CMV2-vector or 3 mg pFLAG-CMV2-D167N (dnCDK9) and harvested after 48 h, or transfected with pSG52A and treated with 30 mM DRB for 48 h. Cells from two pooled transfections were lysed in 1 ml of EBC buffer and duplicate immunoprecipitations were carried out as described above using 0.5 ml of lysate and 4 mg of the EBNA 2 monoclonal antibody PE2 (gift from M Rowe).
Immunoprecipitates were washed three times in EBC buffer, once in ice-cold PBS and then given a final wash in alkaline phosphatase buffer (Roche). Samples were then incubated in 450 ml of alkaline phosphatase buffer in the presence or absence of 45 U of calf intestinal alkaline phosphatase (1 U/ml, Roche) for 30 min at 371C. Proteins were separated using a 7% Tris-acetate gel (Novex, Invitrogen) and Trisacetate running buffer for the length of time recommended by 
GACGAACTGACCACAACACTAGA
Primers were designed using the Primer 3 program (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi) and the sequence of the B95-8 strain of EBV. The parameters of the program were set to select primers between 80 and 120 nucleotides in length with melting temperatures between 59 and 601C and no more than two or three consecutive identical nucleotides. The locations of the primers are given relative to the transcription start site of the Cp. All primer sequences indicated are written in the 5 0 -3 0 orientation. a The locations of primer sets 5 and 6 are given relative to the C promoter start site on the mini-EBV plasmid that drives the expression of the ER/EBNA 2 fusion protein in ER/EB2-5 cells (Kempkes et al., 1995) . The locations of the BZLF-1 control primer sets are given relative to the transcription start site of the BZLF-1 gene.
the manufacturer plus an additional 20 min to achieve maximum separation of the phosphorylated and dephosphorylated forms of the protein.
Immunoblotting SDS-PAGE and immunoblotting was carried out as previously described using prepoured gels (Novex, Invitrogen) (West et al., 2004) . CDK7 was detected using sc-529, CDK8 using sc-1521, CDK9 using sc-7331 and cdc2 using sc-54 (Santa Cruz Biotechnology Inc.). EBNA 2 was detected using PE2.
RNase protection assays
RNase protection assays were carried out essentially as described previously (West and Karn, 1999) . Total RNA was treated twice with 100 U RNase-free DNAse I (10 U/ml, Roche). Approximately 60 mg of total RNA was used for each analysis.
Probes 1 and 2 were generated as previously described (West and Karn, 1999 ) from plasmids pBS SK þ prox and pBS SK þ dist, respectively. Briefly, labelled probes were synthesized from linearized plasmids using 20 U T7 RNA polymerase (20 U/ml, Roche) in the presence of 50 mCi [a-
32 P] UTP (800 Ci/ mmol, Amersham) and purified by urea-PAGE. Protection assays were carried out as previously described (West and Karn, 1999) using 30 000 cpm of probe, 2.5 U/ml RNase T1 (Ambion) and 5 ng/ml RNase A (Sigma).
ChIP assays ER/EB2-5 cells were incubated at 371C for 3 days in the absence or presence of 1 mM b-estradiol prior to chromatin preparation.
ChIP assays were carried out using an adapted version of a previously described protocol (Deng et al., 2003) as described in the Supplementary information available online.
Real-time PCR
Real-time PCR was carried out using a Stratagene Mx4000 PCR machine and the primers indicated in Table 1 . A series of dilutions of input control DNA (1/5, 1/25, 1/125, 1/625) obtained from cells cultured in the presence or absence of bestradiol were used to generate input control standard curves for each primer set. Real-time PCR reactions contained 5 ml of DNA, quantitect SYBR green PCR mix (Qiagen), 150 nmol of forward primer and 150 nmol of reverse primer in a total volume of 25 ml. DNA was amplified by heating samples to 951C for 10 min followed by 40 cycles of 951C for 30 s, 591C for 1 min and 721C for 30 s. Samples were then incubated at 951C for 1 min prior to dissociation curve analysis. Standard curves were used to convert crossing threshold (C t ) values obtained for all samples and the no antibody controls into percentage input values. The no antibody control values were then subtracted from each immunoprecipitation. All analyses were carried out in duplicate.
